Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al.: An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321: 1807–1812. 10.1126/science.1164382 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360: 765–773. 10.1056/NEJMoa0808710 Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al.: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462: 739–744. 10.1038/nature08617 Borodovsky A, Seltzer MJ, Riggins GJ: Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol 2012, 24: 83–89. 10.1097/CCO.0b013e32834d816a Venneti S, Thompson CB: Metabolic modulation of epigenetics in gliomas. Brain Pathol 2013, 23: 217–221. 10.1111/bpa.12022 Reitman ZJ, Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102: 932–941. 10.1093/jnci/djq187 Mirebeau-Prunier D, Le Pennec S, Jacques C, Fontaine JF, Gueguen N, Boutet-Bouzamondo N, et al.: Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PLoS One 2013, 8: e58683. 10.1371/journal.pone.0058683 Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, et al.: Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer 2012, 11: 76. 10.1186/1476-4598-11-76 McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, et al.: Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 2013, 19: 773–784. 10.1158/1078-0432.CCR-12-2638